홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

4-Hydroxybutanoate

HCID 3037032
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
1320-61-2
표준 SMILES
O=C([O-])CCCO
InChIKey
SJZRECIVHVDYJC-UHFFFAOYSA-M
분자식
C4H7O3-
평균 분자량
103.1 g/mol
단동위원소 질량
103.03951908

개요

4-hydroxybutyrate is a 4-hydroxy monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of 4-hydroxybutyric acid. It has a role as an intravenous anaesthetic and an anaesthesia adjuvant. It is a 4-hydroxy monocarboxylic acid anion, a short-chain fatty acid anion and a hydroxy fatty acid anion. It is functionally related to a butyrate. It is a conjugate base of a 4-hydroxybutyric acid.

이름 및 식별자

우선 이름
4-Hydroxybutanoate
IUPAC
4-hydroxybutanoate

이름 및 동의어

4-Hydroxybutanoate4-hydroxybutyrateHydroxybutyrateg-hydroxybutyric acid1320-61-2CHEBI:16724DTXSID10157296Butyric acid, hydroxy-, ion(1-)Butanoic acid, hydroxy-, ion(1-)RefChem:524018Butyric acid, hydroxy, ion(1)DTXCID3079787
이름 더 보기
Butanoic acid, hydroxy, ion(1)691-053-4Gamma Hydroxy butyrate4-HBSJZRECIVHVDYJC-UHFFFAOYSA-MAKOS024437936PD009490AB01563260_01

데이터베이스 식별자

CAS
1320-61-2、591-81-1
PubChem CID
3037032
DTXSID
DTXSID10157296
ChEBI
CHEBI:16724
EC Number
691-053-4

물성

구조 계산 물성

XLogP
0
극성 표면적
60.4 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
2
무거운 원자 수
7
형식 전하
-1
복잡도
54.4

실험 및 물리화학적 성질

Chemical ClassesOther Classes -> Organic Acids
DrugsDEA Schedule I Controlled Substance -> Depressants

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 3건

This chemical does not meet GHS hazard criteria for 100% (2 of 2) of all reports.

Not Classified

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory InformationDEA schedule I controlled substance
Hazards SummarySee Butyric acid.
Hazard Classes and CategoriesNot Classified

독성 정보

Health EffectsChronically high levels of 4-hydroxybutyric acid are associated with the inborn errors of metabolism called: 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency.
Toxicity Summary · 1건

GHB reaches much higher concentrations in the brain and activates GABAB receptors, which are primarily responsible for its sedative effects. GHB receptors are densely expressed in many areas of the brain, including the cortex and hippocampus, and these are the receptors that GHB displays the highest affinity for. There has been somewhat limited research into the GHB receptor; however, there is evidence that activation of the GHB receptor in some brain areas results in the release of glutamate, the principal excitatory neurotransmitter. Activation of both the GHB receptor and GABA(B) is responsible for the addictive profile of GHB. GHB's effect on dopamine release is biphasic,[19] low concentrations stimulate dopamine release via the GHB receptor.[20] Higher concentrations inhibit dopamine release via GABA(B) receptors as do other GABA(B) agonists such as baclofen and phenibut.[21] After an initial phase of inhibition, dopamine release is then increased via the GHB receptor. This explains the paradoxical mix of sedative and stimulatory properties of GHB, as well as the so-called "rebound" effect, experienced by individuals using GHB as a sleeping agent, wherein they awake suddenly after several hours of GHB-induced deep sleep. That is to say that, over time, the concentration of GHB in the system decreases below the threshold for significant GABAB receptor activation and activates predominantly the GHB receptor, leading to wakefulness.

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Route of Elimination: Animal studies indicate that metabolism is the major elimination pathway for sodium oxybate, producing carbon dioxide and water via the tricarboxylic acid (Krebs) cycle and secondarily by beta-oxidation. Succinic acid enters the Krebs cycle where it is metabolized to carbon dioxide and water. Fecal and renal excretion is negligible. 5% renal elimination. Half Life: 30 to 60 minutes

용도 및 제조

UsesUsed as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance.

관련 반응

7건
반응 기록 만들기
HRID 389838 반응식
HRID 389838반응물로uspto-grants-2013_02
HRID 389839 반응식
HRID 389839반응물로uspto-grants-2013_02
HRID 389840 반응식
HRID 389840반응물로uspto-grants-2013_02
HRID 1148632 반응식
HRID 1148632반응물로Training data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1238989 반응식
HRID 1238989반응물로Training data from https://doi.org/10.1039/C8SC04228D (5/10)
HRID 2158239 반응식
HRID 2158239반응물로Training data from https://doi.org/10.1039/C8SC04228D (4/10)
HRID 2321533 반응식
HRID 2321533반응물로Training data from https://doi.org/10.1039/C8SC04228D (10/10)

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).